Drug intelligence / Profile preview

lipiodol + ethanol

Development stage
Unknown
Lead developer
Guerbet
Modality
Small Molecules
Administration
Intra-arterial
01

Overview

Lipiodol + ethanol is a therapeutic mixture used primarily for transarterial embolization ablation (TEA) of hepatocellular carcinoma. The combination creates a dual-action treatment where: 1. Lipiodol (ethiodized oil) serves as a radio-opaque carrier that: - Allows visualization of the treatment delivery under fluoroscopy - Selectively accumulates in tumor tissue - Acts as a temporary embolic agent - Serves as a carrier for ethanol 2. Ethanol functions as a strong protein coagulant that: - Directly inactivates tumor cells in situ - Causes vascular endothelial injury and platelet cohesion - Results in permanent occlusion of tumor-feeding vessels - Leads to tumor infarction without causing collateral circulation The mixture is typically injected through the hepatic artery to target liver tumors, with the ratio of Lipiodol to ethanol varying from 1:1 to 5:1 depending on the specific treatment protocol and tumor characteristics[4][7].

Other names
ethanol-Lipiodol mixtureLEM

Beyond the preview

Go deeper on lipiodol + ethanol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lipiodol + ethanol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call